JNJ Stock Recent News
JNJ LATEST HEADLINES
I added additional shares of Alphabet, PepsiCo, and the Schwab U.S. Dividend Equity ETF to The Dividend Income Accelerator Portfolio to optimize our portfolio's risk-reward, income, and growth balance. Alphabet's attractive valuation, low payout ratio, and strong earnings growth boost our portfolio's dividend growth and capital appreciation potential. PepsiCo combines dividend income and dividend growth, enhancing our portfolio's income and stability.
Dividend stocks are one of the most powerful wealth compounders. The S&P 500 (SNPINDEX: ^GSPC) index offers the perfect example.
JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.
Sales of Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato grew sequentially in the second quarter, marking a positive sign for the broader psychedelics sector, according to Jefferies analysts. Spravato sales grew 29% quarter-over-quarter to $414 million worldwide.
'Mad Money' host Jim Cramer talks how to react when surprise stock pops happen.
Johnson & Johnson JNJ stalled out at resistance around the $165 level. There tends to be resistance at price levels that had previously been resistance.
Earnings season is synonymous with market volatility. Growth-oriented investors may love trading the ups and downs, but more risk-averse investors may look for ways to generate solid returns balanced by steady cash flow.
J&J's diversified business, robust pipeline, and strong free cash flow provide stability despite ongoing legal overhang from talcum powder claims. Legal risks remain a near-term headwind, but I believe any settlement will be manageable for J&J's financial strength and present a buying opportunity. J&J's 63-year dividend growth streak, solid payout ratio, and AAA credit rating make it an attractive choice for long-term, income-focused investors.
IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.
Johnson & Johnson JNJ posted better-than-expected quarterly earnings and raised its FY2025 earnings guidance on Wednesday.